A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

NCT05464420 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2162

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Disease

Interventions

BIOLOGICAL: V116
BIOLOGICAL: PPSV23

Sponsor

Merck Sharp & Dohme LLC